Rat NPFF(1) receptor-mediated signaling: functional comparison of neuropeptide FF (NPFF), FMRFamide and PFR(Tic)amide. 2006

Jin-Chung Chen, and Wei-Hsin Lee, and Pei-Chun Chen, and Ching-Ping Tseng, and Eagle Yi-Kung Huang
Laboratory of Neuropharmacology, Department of Physiology and Pharmacology, Chang-Gung University, 259 Wen-Hwa 1st Road, Tao-Yuan, Kwei-Shan, 333, Taiwan, ROC.

Neuropeptide FF (NPFF) participates in many physiological functions associated with opioids in the mammalian CNS. We established a pheochromocytoma PC-12 cell line clone stably expressing rat NPFF1 receptors. Both NPFF and FMRFamide activated NPFF1 receptors to couple with Gi/o protein and inhibited adenylyl cyclase activity in PC-12/rNPFF1 cells, but there were no effects on MAPKs (ERK1/2 and p38 MAPK) or PI3K/Akt pathway. FMRFamide also inhibited DARPP-32/Thr34 phosphorylation in the presence of forskolin. Similarly, PFR(Tic)amide, a 'super-agonist' of NPFF receptors, inhibited the production of cAMP and slightly decreased DARPP-32/Thr34 phosphorylation in PC-12/rNPFF1 cells. Intracerebroventricular injections of PFR(Tic)amide blocked behavioral sensitization of locomotor activity to amphetamine, and intrathecal injection of PFR(Tic)amide caused a dose-dependent antinociception in vivo in rats. Thus, "over-activation" of NPFF receptors by PFR(Tic)amide induced different bio-effects from those induced by NPFF in vivo.

UI MeSH Term Description Entries
D007276 Injections, Intraventricular Injections into the cerebral ventricles. Intraventricular Injections,Injection, Intraventricular,Intraventricular Injection
D007278 Injections, Spinal Introduction of therapeutic agents into the spinal region using a needle and syringe. Injections, Intraspinal,Injections, Intrathecal,Intraspinal Injections,Intrathecal Injections,Spinal Injections,Injection, Intraspinal,Injection, Intrathecal,Injection, Spinal,Intraspinal Injection,Intrathecal Injection,Spinal Injection
D008297 Male Males
D009043 Motor Activity Body movements of a human or an animal as a behavioral phenomenon. Activities, Motor,Activity, Motor,Motor Activities
D009479 Neuropeptides Peptides released by NEURONS as intercellular messengers. Many neuropeptides are also hormones released by non-neuronal cells. Neuropeptide
D009842 Oligopeptides Peptides composed of between two and twelve amino acids. Oligopeptide
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D005576 Colforsin Potent activator of the adenylate cyclase system and the biosynthesis of cyclic AMP. From the plant COLEUS FORSKOHLII. Has antihypertensive, positive inotropic, platelet aggregation inhibitory, and smooth muscle relaxant activities; also lowers intraocular pressure and promotes release of hormones from the pituitary gland. Coleonol,Forskolin,N,N-Dimethyl-beta-alanine-5-(acetyloxy)-3-ethenyldodecahydro-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-1H-naphtho(2,1-b)pyran-6-yl Ester HCl,NKH 477,NKH-477,NKH477
D000262 Adenylyl Cyclases Enzymes of the lyase class that catalyze the formation of CYCLIC AMP and pyrophosphate from ATP. Adenyl Cyclase,Adenylate Cyclase,3',5'-cyclic AMP Synthetase,Adenylyl Cyclase,3',5' cyclic AMP Synthetase,AMP Synthetase, 3',5'-cyclic,Cyclase, Adenyl,Cyclase, Adenylate,Cyclase, Adenylyl,Cyclases, Adenylyl,Synthetase, 3',5'-cyclic AMP
D000661 Amphetamine A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE. Desoxynorephedrin,Levoamphetamine,Phenopromin,l-Amphetamine,Amfetamine,Amphetamine Sulfate,Amphetamine Sulfate (2:1),Centramina,Fenamine,Mydrial,Phenamine,Thyramine,levo-Amphetamine,Sulfate, Amphetamine,l Amphetamine,levo Amphetamine

Related Publications

Jin-Chung Chen, and Wei-Hsin Lee, and Pei-Chun Chen, and Ching-Ping Tseng, and Eagle Yi-Kung Huang
February 2000, Peptides,
Jin-Chung Chen, and Wei-Hsin Lee, and Pei-Chun Chen, and Ching-Ping Tseng, and Eagle Yi-Kung Huang
December 2003, Peptides,
Jin-Chung Chen, and Wei-Hsin Lee, and Pei-Chun Chen, and Ching-Ping Tseng, and Eagle Yi-Kung Huang
December 2009, Neurochemistry international,
Jin-Chung Chen, and Wei-Hsin Lee, and Pei-Chun Chen, and Ching-Ping Tseng, and Eagle Yi-Kung Huang
November 2000, Peptides,
Jin-Chung Chen, and Wei-Hsin Lee, and Pei-Chun Chen, and Ching-Ping Tseng, and Eagle Yi-Kung Huang
June 2002, The Journal of comparative neurology,
Jin-Chung Chen, and Wei-Hsin Lee, and Pei-Chun Chen, and Ching-Ping Tseng, and Eagle Yi-Kung Huang
May 2006, Peptides,
Jin-Chung Chen, and Wei-Hsin Lee, and Pei-Chun Chen, and Ching-Ping Tseng, and Eagle Yi-Kung Huang
January 1997, Brain research bulletin,
Jin-Chung Chen, and Wei-Hsin Lee, and Pei-Chun Chen, and Ching-Ping Tseng, and Eagle Yi-Kung Huang
July 2010, Peptides,
Jin-Chung Chen, and Wei-Hsin Lee, and Pei-Chun Chen, and Ching-Ping Tseng, and Eagle Yi-Kung Huang
March 2005, Molecular pharmacology,
Jin-Chung Chen, and Wei-Hsin Lee, and Pei-Chun Chen, and Ching-Ping Tseng, and Eagle Yi-Kung Huang
April 2008, Regulatory peptides,
Copied contents to your clipboard!